Egalet a/s is focused on the development of innovative pharmaceutical products utilizing the company’s proprietary, erosion-based, controlled release technology, Egalet® and a novel system, Parvulet®, aimed at the pediatric market. Egalet’s pipeline consists of four products in clinical development, two of which are entering late-stage pivotal studies for the cardiovascular and pain markets. Egalet is also making its technologies available to pharmaceutical companies wanting to optimize the formulation and delivery of their drugs.

With improved consumer acceptance and highly competitive development and production costs, Egalet aims to become a preferred partner for the pharmaceutical industry with its strategy for controlling drug development efforts from product formulation and clinical testing, to regulatory submissions and manufacturing.